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Abstract: Polycystic ovary syndrome (PCOS) is a heterogeneous condition characterized by 
anovulation, hyperandrogenism, and polycystic ovaries. Because of the heterogeneous nature 
of PCOS, women affected by the condition often require a customized approach for ovulation 
induction when trying to conceive. Treating symptoms of PCOS in overweight and obese women 
should always incorporate lifestyle changes with the goal of weight-loss, as many women with 
PCOS will ovulate after losing 5%–10% of their body weight. On the other hand, other factors 
must be considered including the woman’s age, age-related decline in fertility, and previous 
treatments she may have already tried. Fortunately, multiple options for ovulation induction 
exist for women with PCOS. This paper reviews specific ovulation induction options available 
for women with PCOS, the benefits and efficacy of these options, and the related side effects 
and risks women can anticipate with the various options that may affect treatment adherence. 
The paper also reviews the recommended evidence-based strategies for treating PCOS-related 
infertility that allow for incorporation of the patient’s preference. Finally, it briefly reviews 
emerging data and ongoing studies regarding newer agents that have shown great promise as 
first-line agents for the treatment of infertility in women with PCOS.
Keywords: polycystic ovary syndrome, anovulation, clomiphene citrate, letrozole, metformin, 
obesity
Treating PCOS-related infertility in the 21st 
century
Stein and Leventhal initially described polycystic ovarian syndrome (PCOS) with 
associated amenorrhea in 1935.1 They also described a strategy called an ovarian wedge 
resection that seemed to be effective in treating the associated infertility. Since that 
time, numerous descriptions and diagnostic criterion for the condition have emerged. 
While it is fortunate that other treatment strategies have emerged, because varying 
diagnostic criteria have been used to define PCOS over the years, it can be difficult 
to determine the external validity of older published PCOS literature. More recently, 
increasing attention to the exact definitions of PCOS and the quality of clinical stud-
ies investigating treatments for infertility related to PCOS have greatly advanced our 
understanding of the nuances involved in treating PCOS-related infertility. The fol-
lowing sections review the evidence for the efficacy of various infertility treatment 
strategies as well as the side effects and risks that may affect patient adherence. Overall, 
this review examines the clinical experience and evidence for treating PCOS-related 
infertility so that a treatment plan can be constructed that incorporates patient prefer-
ence and is mutually satisfactory for the patient and the clinician.
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A current working definition  
of PCOS
As previously mentioned, PCOS was originally described by 
Stein and Leventhal in their classic paper published in the 
American Journal of Obstetrics and Gynecology in 1935.1 In 
this paper, Stein and Leventhal described seven women with 
enlarged, polycystic ovaries, obesity, hirsutism, and chronic 
anovulation. Recognizing the need to establish diagnostic 
criteria for PCOS to allow for well-designed research and 
clinical trials related to PCOS, an expert panel sponsored by 
the National Institutes of Health (NIH) developed a widely 
accepted definition for PCOS in 1990.2 This definition 
included the following major criteria for defining PCOS: 
hyperandrogenism and/or hyperandrogenemia, menstrual 
dysfunction, and the exclusion of other known disorders. 
While these criteria helped to clarify the standards for 
diagnosis, treatment, and research, debate still existed on 
the criteria that should be used to define the condition. In 
2003, another expert conference was convened in Rotterdam, 
The Netherlands. This conference was sponsored by the 
European Society for Human Reproduction and Embryol-
ogy and the American Society for Reproductive Medicine. 
At this conference, the experts agreed that PCOS should be 
defined by the presence of two of the following characteris-
tics: oligo and/or anovulation, clinical and/or biochemical 
signs of hyperandrogenism, and/or polycystic ovaries on 
an ultrasound. This definition was broader than the NIH 
criteria and placed less emphasis on the hyperandrogenism 
requirement. More recently, the Androgen Excess and PCOS 
Society, an organization comprising international experts in 
the area of PCOS, published a report outlining the follow-
ing characteristics as being key to the diagnosis of PCOS: 
hyperandrogenism (clinical and/or biochemical), ovarian 
dysfunction (oligo-anovulation and/or polycystic ovaries), 
and the exclusion of related disorders. In this definition, 
the experts re-established hyperandrogenism as the key to 
PCOS diagnosis.
While some of the debate surrounding the definition of 
PCOS may be related to semantics for research purposes 
rather than clinical care, establishing clear diagnostic criteria 
for PCOS is necessary for embarking on sophisticated mecha-
nistic research involving the study of PCOS and for applying 
the results of clinical trials to individual patients.
Regardless of the criteria used to diagnose women 
affected by PCOS, it is the most common   endocrinopathy 
affecting  women  of  reproductive  age.  Somewhere 
between 6%–8% of women are affected by this syndrome 
  worldwide.3 In addition to the hyperandrogenism and 
  anovulation/  oligomenorrhea that characterize the condition, 
depression, and long-term risks for the development of 
endometrial cancer, diabetes, and cardiovascular disease are 
also significant risks.4–6 If no work up has been performed 
on a woman presenting with a clinical picture of PCOS, 
we will typically screen these women for other causes of 
ovulation disorders including thyroid disease, Cushing’s 
syndrome, and premature ovarian failure when appropriate. 
We also typically check a serum testosterone level (total), 
and a 17-hydroxyprogesterone value in addition to routine 
screening tests recommended by current guidelines includ-
ing a complete serum lipid panel and a 2 hour, 75 gram oral 
glucose tolerance test.6
Opportunity for preconception 
counseling in infertile women  
with PCOS: an opportunity  
for education and improved lifestyle 
for a healthier outcome
Screening for glucose intolerance and 
diabetes – to take metformin or not?
Current guidelines for treating women with PCOS recom-
mend screening for glucose intolerance.6 Of the available 
options for screening (fasting glucose, hemoglobin A1c, 
and the 2 hour, 75 gram oral glucose tolerance test), the 
2 hour, 75 gram oral glucose tolerance test may be the most 
sensitive means of detecting glucose intolerance.5,7 This 
method may also be helpful for determining if a woman is a 
pregestational diabetic. For women who are not diabetic, but 
who are glucose intolerant, the addition of metformin may 
lead to improved insulin sensitivity and a better metabolic 
profile and response to clomiphene citrate (CC) for ovula-
tion induction.8   Metformin will likely have no benefit for 
non-obese women with PCOS who do not show glucose 
intolerance after screening. Whether or not metformin reduces 
the risk of developing gestational diabetes once pregnancy 
occurs is unknown although more recent data suggests that 
it does not.9 Including this background information for 
women when counseling them on their treatment options for 
ovulation induction may be helpful as metformin was touted 
as the mainstay of PCOS treatment by many for years, but 
unfortunately, many women experience gastrointestinal side 
effects such as nausea and diarrhea. Due to the risks of asso-
ciated lactic acidosis, metformin should be started at a low 
dose and built up over time, and only if women are proven to 
have normal renal and hepatic functioning. We recommend 
starting at 500 mg po daily for one week with an additional   
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500 mg daily per week until a 2000 mg daily dose is reached. 
The extended release formulation may be beneficial for 
women who have difficulty with that dosage level.
Weight loss
While infertility is an emotionally difficult condition for 
any couple to face, it offers an important opportunity 
for thorough preconception counseling and intervention 
for couples hoping to conceive. In women with PCOS, 
this opportunity can be especially beneficial as these 
women face increased risks of gestational diabetes and 
preeclampsia during pregnancy. These risks, along with the 
anovulation associated with PCOS, are often exacerbated 
by the excess body weight that often accompanies PCOS. 
Overweight and obese women with anovulation/oligom-
enorrhea and PCOS will often ovulate spontaneously 
after losing only 5%–10% of their body weight. When 
setting a timeline and goal for weight loss, it is important 
to keep the woman’s age in mind as fertility decreases 
more rapidly after age 35. Morbidly obese women with 
a body mass index (BMI) of 40 kg/m2 or greater may 
require greater weight loss.10 For many women, clinically 
significant weight loss may be difficult to achieve and 
sustain. Encouraging partner involvement in the weight 
loss plan may be helpful. Reviewing previous attempts at 
weight loss with women and encouraging them to consider 
commercial weight loss programs may also be beneficial 
along with a referral to a dietician and an exercise facility. 
Setting a goal for weight loss and a plan for follow up are 
also important. This is also an opportune time to review 
the long-term health risks associated with obesity and 
PCOS such as type 2 diabetes, endometrial cancer, and 
cardiovascular disease. Reviewing these risks with women 
at this crucial time may encourage them to act.
For obese women with PCOS who are over 40 kg/m2 or 
women who are 35 kg/m2 with co-morbidities like diabetes, 
bariatric surgery may be an option for achieving sustainable 
weight loss. Again, it may be necessary for these women to 
lose more than 5%–10% of their body weight to see improve-
ments in ovulation. On the other hand, bariatric surgery is 
not without risks and requires a commitment that many 
people are not willing to make. Nevertheless, this option 
is worth mentioning to women who qualify, along with a 
discussion of the time commitment required. Most surgeons 
recommend that women wait for a period of one year after 
bariatric surgery prior to conception so that the maximum 
benefit of the weight loss associated with the procedure can 
be achieved. Many women have successfully conceived prior 
to the one-year wait period and this may be reasonable for 
older patients.11 It is important to warn patients that while 
they may achieve successful weight loss, fertility treatments 
may still be required.12
Given the time commitment required for weight loss, 
a discussion of patient age and baseline fertility is war-
ranted since delaying fertility treatment may be detrimental 
to a woman’s prospects for childbearing. Recent cross-
sectional studies by the Society for Assisted Reproductive 
Technologies (SART) present convincing evidence on the 
impact of obesity on fertility versus the impact of age. In 
these studies, researchers have shown that increasing obe-
sity is associated with decreased chances of conception in 
women younger than age 35 undergoing assisted reproductive 
technologies (ART).13 Conversely, in women over the age 
of 35, obesity has less of an impact on the success of ART 
and age becomes the overriding factor.13,14 While attempts 
at weight loss and lifestyle improvements should never be 
discouraged in overweight and obese women, women must 
be fully informed of the realistic expectations they may have 
for fertility with increasing age.
Modifiable risk factors: dietary 
interventions
Emerging epidemiologic data from the Nurses’ Health 
Study II (NHSII) suggest that certain foods may be associ-
ated with ovulation disorders like PCOS.15 While control-
ling for BMI, nutritional epidemiologists involved with 
NHSII have demonstrated that certain dietary choices may 
be associated with higher risks of anovulation. The results 
of these epidemiologic investigations led by nutritional 
epidemiologist, Jorge Chavarro, MD, PhD, suggest that 
saturated animal fats and trans-fats found in commercially 
baked goods and some fried fast foods are associated 
with ovulatory infertility while fats found in foods such 
as salmon, tuna, and nut sources may be beneficial to 
promoting ovulatory function.16 Dr Chavarro’s work also 
shows that foods containing refined sugars are detrimental 
to ovulatory fertility while carbohydrate-rich foods with a 
lower glycemic index may be beneficial.17 Finally, these 
studies have shown that daily multi-vitamin use may be 
beneficial for women with PCOS-related infertility along 
with supplemental iron intake.18,19 Given that folic acid is 
an important supplement for any woman of reproductive 
age for preventing neural tube defects, a multi-vitamin 
containing folic acid should always be encouraged. 
  Education regarding patient-modified interventions such as 
these may be empowering for some patients and should be 
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discussed along with the disclaimer that prospective trials 
incorporating dietary recommendations like these have yet 
to be completed; therefore, their impact on ovulation and 
reproductive outcomes is yet to be determined.
When time runs out: moving  
on from lifestyle intervention  
to ovulation induction
As mentioned, fertility declines with age. This decline   
increases rapidly after age 35. It has been suggested in the 
SART literature that women younger than 35 aim for a BMI 
of less than 30 kg/m2.20 Women over age 35 should aim for a 
BMI of less than 35 kg/m2. For these women, it is unknown 
whether achieving a BMI of less than 35 kg/m2 will lead to 
an improved response to fertility treatment or a healthier 
pregnancy outcome. It is both realistic and reasonable to 
propose fertility treatment for otherwise healthy overweight 
and obese women with PCOS who have tried to lose weight 
unsuccessfully, and this approach is supported by the Ethics 
Committee of the American Society for Reproductive 
Medicine.21 While obesity is associated with decreased 
success in fertility treatments22 and increased risks of adverse 
pregnancy outcomes, a BMI at which it is unsafe to provide 
fertility treatments has not been established and likely 
never will be since there are numerous examples of women 
with excessive BMIs who have successfully conceived and 
delivered. Ultimately, a conversation between the physician 
and patient must take place to determine the right course of 
action and to understand the evidence regarding the competing 
risks of time required for weight loss and the effects of age 
on fertility and response to fertility treatment.
The data for ovulation induction  
in women with PCOS: past, present 
and future
Treatments of the past: wedge resection 
and ovarian drilling
As mentioned in the introduction, Stein and Leventhal 
described wedge resection for ovulation induction in women 
with PCOS.1 While this method can help women achieve 
spontaneous ovulation, it is invasive with significant risk 
of blood loss during surgery, post-operative adhesion for-
mation, and time-loss for recovery. Ovarian drilling has 
also been shown to be efficacious in inducing spontaneous 
ovulation and pregnancy.23–25 It offers an advantage over 
ovarian wedge resection as it is less likely to be associated 
with significant blood loss, and is easily conducted via a 
laparoscopic technique. This method is helpful in cases 
where women are resistant to ovulation induction with oral 
medications and want to avoid gonadotropin injections. 
However, it is also associated with pelvic adhesion formation 
and decreased ovarian reserve over time as a portion of the 
ovary is destroyed through the drilling process. Both of these 
surgical interventions have been largely replaced with oral 
ovulation induction methods with gonadotropin injections, 
while ARTs are reserved for women who fail to ovulate or 
conceive with oral medications.
First-line treatment: CC, metformin,  
or both?
CC is a convenient, accessible, and relatively inexpensive 
treatment that has been a mainstay for ovulation induction in 
women with PCOS for over 40 years. Unfortunately, a frac-
tion of women with PCOS are resistant to CC. In the 1990s, 
metformin was identified as a solution to such cases and 
gained popularity as a first-line alternative to CC because it 
was thought to improve metabolic functioning while decreas-
ing the risk PCOS in patients who faced developing gesta-
tional diabetes during pregnancy.8,9,26 Numerous studies have 
emerged that compare the two agents for ovulation induction 
with disparate results.27,28 Finally, the NIH-sponsored Repro-
ductive Medicine Network (NIH-RMN) undertook a large, 
multi-centered trial comparing CC, metformin, and both as 
agents for ovulation induction.29 In this intention-to-treat 
trial, CC was clearly better as a first-line agent for achiev-
ing pregnancy and live birth when compared to metformin 
alone. The combination of CC with metformin was equivocal, 
although there was some evidence that the combination arm 
may have helped in PCOS patients with morbid obesity. Some 
have argued that it was poor compliance with metformin 
therapy that resulted in the superior results of the CC-alone 
arm,30 but a secondary analysis of the data has demonstrated 
that adherence in both the metformin-only and combined-
metformin-CC arms was within the reported expectations 
for clinical trials.31 The authors of the study concluded that 
failure to comply with metformin dosing was not the reason 
for low ovulation and pregnancy rates in the metformin arms 
of the trial.
Common side-effects associated with CC include hot 
flashes and labile mood. Visual disturbances and headaches 
should warrant discontinuation and consideration of switch-
ing to an alternative agent for ovulation induction. We 
recommend starting with a daily dose of CC 50 mg daily 
cycle for 3–7 day with a luteal phase progesterone level to 
document ovulation. If the progesterone value is ,2 ng/mL 
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and the woman’s cycle is longer than 35 days with a negative 
urine pregnancy test, we recommend inducing menses and 
proceeding with another cycle of CC and increasing the dose 
by an additional 50 mg cycle for 3–7 days. These steps are to 
be repeated until ovulation is achieved to a maximum dose of 
150 mg to 200 mg depending on the associated side effects. 
This process can be frustrating and it is often important to 
encourage women to be persistent if ovulation is not achieved 
in the first one or two cycles to help with adherence.31
For women who are resistant to ovulation induction with 
CC alone, the addition of metformin may be beneficial.26 In 
a recent publication, we demonstrated that initial concomi-
tant treatment with CC and metformin may be superior to 
CC alone.32 We argue that the sample size employed in the 
NIH-RMN trial was not large enough to detect the clini-
cally significant difference that may exist in treating women 
with CC alone versus CC and metformin together.33 Again, 
screening for insulin resistance in women with PCOS prior to 
treatment may indicate which women will benefit from initial 
concomitant treatment with both CC and metformin.
As previously discussed, metformin – labeled by some 
as “Vitamin M” – was the first-line for treating infertility in 
women with PCOS.34 Due to the heterogeneous nature of the 
PCOS, not all women will respond to metformin; therefore, it 
should be reserved for women with proven insulin-resistance. 
Again, we recommend a 2 hour, 75 gram oral glucose toler-
ance test for screening. We also recommend that it not be 
used alone in the treatment of PCOS-related infertility as the 
results of the NIH-RMN trial described above clearly demon-
strate the inadequacy of metformin alone when compared to 
CC alone and CC and metformin together. For women who 
are insulin-resistant, we recommend an approach of CC at 
50 mg daily cycle for 3–7 days with a daily dose of 2000 mg 
of metformin. As outlined above, metformin should be started 
at a daily dose of 500 mg and built up over a period of weeks 
to reach the 2000 mg dose.
Letrozole as the future first-line 
treatment
Aromatase inhibitors prevent the aromatization of testoster-
one to estrogen and are used primarily as adjunctive agents 
to treat breast cancer. The first report of letrozole’s efficacy at 
inducing ovulation in women with PCOS emerged in 2001.35 
Letrozole is relatively well tolerated in terms of the associ-
ated side effects such as gastrointestinal disturbances and hot 
flashes. Furthermore, letrozole has a shorter half-life than CC. 
When used for ovulation induction, letrozole is associated 
with a thicker endometrium compared to CC and multiple 
gestations may be less common. While letrozole appears to be 
efficacious at inducing ovulation, it is yet to be demonstrated 
in adequately designed clinical trials whether it results in 
higher pregnancy rates and an improved chance at singleton 
pregnancy compared to CC.36–38   Fortunately, the RMN has 
initiated a large, multi-centered trial to investigate the effect 
of letrozole versus CC in infertile women with PCOS.39 The 
primary outcome of this trial is live birth. Important second-
ary outcomes include, among others, singleton pregnancy, 
incidence of first trimester fetal demise, time to pregnancy, 
quality of life while on treatment, and cost-effectiveness.
Letrozole is currently reserved for women with PCOS-
related infertility who do not respond to ovulation induction 
with CC or who cannot tolerate its side effects. We typically 
prescribe 5 mg of letrozole for a 3–7 day cycle with a mid-
luteal serum progesterone level to document ovulation.
If ovulation is not achieved with lifestyle interventions 
or oral agents or a woman fails to conceive in a given time 
frame, we recommend moving on to a more aggressive 
treatment. We do not recommend treating women with 
ovarian wedge resection or laparoscopic ovarian drilling. We 
will typically treat a woman with ovulation induction agents 
for up to six ovulatory cycles provided that tubal patency and 
a reasonable semen analysis have been noted. In general, if a 
woman with PCOS is not pregnant after six ovulatory cycles 
and she is ready to move on to other treatment options, we 
will do so.
When all else fails: controlled 
ovarian hyperstimulation and  
in vitro fertilization
Controlled ovarian hyperstimulation  
with injectable medications
We reserve controlled ovarian hyperstimulation (COH) for 
women with PCOS who have failed ovulation induction with 
oral agents. Our goal in treating PCOS patients with COH 
is to achieve monofollicular development. To achieve this 
goal, a lower starting dose of gonadotropin is recommended 
compared to what is typically used in women with other 
indications for COH. We will typically start women with 
PCOS with 75 units daily of a gonadotropin product with a 
serum estradiol level planned for the morning of the fourth 
treatment day. Women must be warned of the risk of cycle 
cancellation if too many follicles are recruited, the risk of 
ovarian hyperstimulation (OHSS), and the risk of higher 
order multiple gestation pregnancy if they choose this mode 
of treatment.25 There are a number of factors that may affect a 
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woman’s decision whether or not to pursue COH or skip COH 
and move directly to in vitro fertilization. These include the 
costs of the procedures at an individual center, insurance cov-
erage requirements if she has infertility insurance benefits, 
and access to centers that provide in vitro fertilization because 
centers with facilities for IVF are often concentrated in areas 
of high population density and women may have to travel for 
hours to get to one of these facilities.40 Despite these factors, 
it may be reasonable for some woman to consider IVF over 
COH given the higher success rates associated with IVF and 
the option for single embryo transfer that exists with lower 
risks for multiple gestation pregnancy. Given the higher 
costs associated with IVF, it may be helpful to discuss IVF 
with women who have PCOS-related infertility early on 
so they may start to plan ahead should they need to utilize 
these services.
ART: in vitro fertilization
IVF offers all women the most effective mode of achieving 
pregnancy in a single cycle.41 On the other hand, IVF may 
be cost-prohibitive for some women, it is time consuming, 
and is associated with risks related to OHSS, anesthesia, and 
surgical complications such as bleeding and bowel/bladder 
injury. For women with PCOS who have not responded to 
treatment with more conservative options, or for women 
with PCOS who have other conditions that require IVF 
(blocked fallopian tubes, male partner with low sperm 
counts, or genetic conditions amenable to intervention with 
preimplantation genetic diagnosis testing) the benefits of IVF 
may outweigh the risks. For any woman considering IVF 
treatment, we recommend consulting the SART to obtain 
information regarding facilities that provide IVF services.42 
We also recommend investigating the Centers for Disease 
Control website on ART for additional information regarding 
factors other than success rates to consider when choosing an 
IVF facility.43 Couples will often consider only one to two 
cycles of IVF so it is imperative that they are well informed 
of the success rates in various IVF facilities and the qualifica-
tions of their providers.
A recent study found that centers with high-performing 
IVF programs share common qualities that may be helpful 
for patients and referring physicians.44 One of these com-
monalities is the selective use of blastocyst embryo transfer 
which may improve selection for single embryo transfer in 
IVF. Single embryo transfer may be an especially important 
option for women with PCOS as they may be at increased 
risk for pregnancy complications if they were to conceive 
with multiple gestations given their predisposition for gesta-
tional diabetes and preeclampsia. Medical societies like the 
American Society for Reproductive Medicine and patient 
advocate groups like RESOLVE are also helpful for couples 
seeking additional information.45,46
Table 1 compares the approximate success rates of vari-
ous oral ovulation induction agents, COH, and IVF along 
with their associated side-effects, risks, and relative costs.
Patient treatment preferences  
for PCOS-related infertility
Unfortunately, the data are sparse when it comes to incor-
porating patient preference in the management of PCOS-
related infertility. We found one article when we performed 
a MEDLINE search for published data using the keywords, 
“patient preference” and “polycystic ovary syndrome.” This 
article entitled, “Treatment preferences and trade-offs for 
ovulation induction in CC-resistant patients with polycystic 
ovary syndrome,” assessed the preferences and trade-offs for 
laparoscopic electrocautery of the ovaries relative to ovula-
tion induction with FSH injections in women with PCOS 
who were resistant to ovulation induction with CC.47 The 
data presented in this article suggest that women are open 
to discussing different treatment options, while weighing the 
risks and benefits of each.
A discussion of the available options should include a 
thorough explanation of normal menstrual cycles and ovula-
tion and an explanation of how the various strategies work, 
their associated risks and benefits, and their cost and efficacy. 
Unfortunately, inducing ovulation in women with PCOS 
often requires a trial-and-error process with different medi-
cations and lifestyle modifications. The recommendations 
outlined in this review are consistent with an evidence-based 
approach to managing PCOS-infertility in a timely, safe, 
and effective manner. Greater transparency regarding the 
common difficulties encountered when inducing ovulation 
in women with PCOS will likely be helpful for improving 
patient compliance with treatment, although this has not been 
studied specifically in women with PCOS.
When it comes to patient preference in the management 
of PCOS-related infertility, the bottom line is that women 
with infertility ultimately want to conceive.47 Personalized 
treatment algorithms are often dictated by cost, insurance 
coverage for fertility treatment, and the effectiveness of 
the various medications in individuals. How these various 
factors drive a woman’s treatment trajectory is yet to be 
determined, but it is likely that women’s choices are often 
driven by cost and the out-of-pocket-expenses associated 
with the   strategies. In our synthesized data incorporating 
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side effects and efficacy into decisions for treating women 
with PCOS, an approach that combines metformin and CC 
for initial treatment was the best initial therapy for ovula-
tion induction in women with PCOS, although letrozole was 
included in the study. Forthcoming data from the NIH-RMN 
reports will help inform the future use of letrozole in this 
population.
Keeping women informed, keeping 
the dialog open, and presenting a 
global perspective on PCOS-related 
infertility treatment
Because of the heterogeneous nature of the presentation of 
PCOS, it often takes some troubleshooting and trial and error 
to determine the best course of action. As mentioned above, 
we recommend screening women with PCOS for related co-
morbidities as outlined by practice guidelines.6 This screening 
includes checking women for glucose intolerance. If a woman 
is glucose intolerant, she may benefit from treatment with 
metformin, but should be warned of side effects and should 
never be treated with metformin alone if ovulation induction 
and pregnancy is the goal. If a woman is overweight or obese, 
lifestyle intervention with the goal of weight loss is also rec-
ommended, but is not always rational if a woman has failed 
numerous attempts at weight loss in the past or if she is older 
than 35 years. CC is the proven first-line agent for ovulation 
induction in women with PCOS, but we are still anticipating 
the results from the NIH-RMN trial as letrozole may prove 
to be equally, if not more, efficacious at achieving pregnancy 
and live birth with reduced risk of multiple gestations.39 If 
these less expensive, easily accessed options prove ineffective, 
COH or IVF are possible although they are associated with 
increased costs, increased time commitment, and increased 
risks of complications such as ovarian hyperstimulation and 
multiple gestations.
The good news is infertile women with PCOS have 
options. It is up to us to ensure that we are fully versed on these 
options and that we are proactive in educating our patients 
to ensure that they do not miss the window of opportunity to 
achieve their family-building goals. If a   general practitioner 
does not have the time to spend counseling and managing 
women struggling with PCOS-related infertility, a referral 
to a specialist in reproductive medicine is appreciated by all 
the parties involved.
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